Ganciclovir extended release - Orbis Biosciences
Alternative Names: ORB-211Latest Information Update: 28 Jun 2023
At a glance
- Originator Orbis Biosciences
- Class Antineoplastics; Antivirals; Hypoxanthines; Small molecules
- Mechanism of Action DNA-directed DNA polymerase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- No development reported Cytomegalovirus infections
Most Recent Events
- 28 Jun 2023 No recent reports of development identified for preclinical development in Cytomegalovirus infections in USA (Intratympanic, Controlled release)
- 04 May 2020 Orbis Biosciences has been acquired by Adare Pharmaceuticals
- 29 May 2019 Orbis Biosciences has patents and corresponding applications covering sustained release particle formulations, in USA, Canada, Europe, as well as a worldwide application